Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean. [PDF]
J Pharm Policy PractEspín J +4 more
europepmc +1 more source
Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis. [PDF]
Front ImmunolSu Y +8 more
europepmc +1 more source
A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema. [PDF]
Front PharmacolZhai G, Ren X, Xu B, Mi D.
europepmc +1 more source
Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care. [PDF]
Ophthalmol TherGil-Rojas Y +4 more
europepmc +1 more source
Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]
Int J Technol Assess Health CareHussain A, Fairbairn R, Khan SK.
europepmc +1 more source
Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre. [PDF]
CureusSourla E, Zaheer N, Chavan R.
europepmc +1 more source
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? [PDF]
Pharmacoecon OpenRodríguez-Lago I +6 more
europepmc +1 more source
Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]
Front OncolMadar IH, Kammarambath SR.
europepmc +1 more source
Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan. [PDF]
J Pharm Policy PractMamiya H, Fukasawa T, Kawakami K.
europepmc +1 more source
Impact on hospitals of price reductions for physician-administered biologics. [PDF]
Health Aff SchRobinson JC +3 more
europepmc +1 more source